Akihiro TsujimuraPresident and Representative Director

Mitsubishi Tanabe Pharma Corporation has been providing patients with medicines and treatments around the world for over 340 years since Tanabe Seiyaku Co., Ltd. (originally TANABEYA Gohei), the forerunner of our company, was established in 1678 in Osaka, as a family business to produce and sell its proprietary TANABEYA Infusing Medicine, earning the trust of healthcare professionals, patients, their families, and other stakeholders.

“Creating hope for all facing illness.” It is our mission.
In recent years, medical needs have become increasingly sophisticated and diversified due to advances in science and digital technologies. At the same time, the diversification of drug discovery modalities and the challenge of addressing refractory diseases have made new drug development more difficult. To adapt these environmental changes and continue growing as a Japanese pharmaceutical company, we aim to maintain a solid business foundation in Japan while expanding globally, with a focus on North America. Achieving this goal requires maximizing the value of our global products and enhancing our research and development pipeline. Building on the experience we have cultivated over the years, we will actively integrate new technologies and continue to advance initiatives that increase our corporate value. Through these efforts, we continue to be committed to contributing to society via our pharmaceuticals.

RADICAVA was launched in 2017 in the U.S. as a new treatment for amyotrophic lateral sclerosis (ALS), a disease for which no new drug had been available for more than 20 years. In 2022, we launched RADICAVA, as an oral suspension formulation. We are also developing digital technologies for early diagnosis and medication support for ALS. Our goal is not just to create a drug: rather, we continue to create new value by putting ourselves in our patients’ shoes.

With your flexible thinking and new powers without fear of failure, we look forward to creating innovative values and contributing together to patients, their families, and society.